Abstract
The local milieu of malignant tumor cells has key roles in cancer progression. A major component of the niche is the extracellular matrix (ECM), a complex interdigitating meshwork of macromolecules with multiple biophysical and biochemical characteristics. Although tightly controlled during normal tissue development and homeostasis, the ECM is mostly deregulated and becomes disorganized in cancer. Abnormal ECM has an impact on cancer progression by promoting tumor malignancy and metastatic dissemination. Importantly, the altered ECM in tumor is associated with deregulated ECM-regulating enzymes (matrix metalloproteinases, lysyl oxidase, urokinase plasminogen activator, and cysteine cathepsin). Excess expression of ECM-regulating enzymes alters behavior of cancer cells in the tumor niche, and its sustained upregulation results in the progressive breakdown of normal ECM which is replaced by tumor-derived ECM, thereby allowing tumor malignancy and cancer cell dissemination. Thus, ECM-regulating enzymes act as essential mediators of deregulating and disorganizing ECM. In this chapter, we will review and discuss how ECM-regulating enzymes generate disruption of ECM homeostasis and contribute to cancer progression, especially cancer metastasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kim ES, Glisson BS (2003) Treatment of metastatic head and neck cancer: chemotherapy and novel agents. Cancer Treat Res 114:295–314
Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97(3):545–553
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432(7015):332–337
Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ, Werb Z (1999) The stromal proteinase mmp3/stromelysin-1 promotes mammary carcinogenesis. Cell 98(2):137–146
Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM (2005) Tensional homeostasis and the malignant phenotype. Cancer Cell 8(3):241–254
Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088):1222–1226
Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM (2009) Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139(5):891–906
Hynes RO (2009) The extracellular matrix: not just pretty fibrils. Science 326(5957):1216–1219
Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8(3):221–233
Cox TR, Erler JT (2011) Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 4(2):165–178
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196(4):395–406
Gjorevski N, Nelson CM (2009) Bidirectional extracellular matrix signaling during tissue morphogenesis. Cytokine Growth Factor Rev 20(5–6):459–465
Erler JT, Weaver VM (2009) Three-dimensional context regulation of metastasis. Clin Exp Metastasis 26(1):35–49
Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123(Pt 24):4195–4200
Harburger DS, Calderwood DA (2009) Integrin signalling at a glance. J Cell Sci 122(Pt 2):159–163
Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119(Pt 19):3901–3903
Leitinger B, Hohenester E (2007) Mammalian collagen receptors. Matrix Biol 26(3):146–155
Xian X, Gopal S, Couchman JR (2010) Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res 339(1):31–46
Schmidt S, Friedl P (2010) Interstitial cell migration: integrin-dependent and alternative adhesion mechanisms. Cell Tissue Res 339(1):83–92
Ozbek S, Balasubramanian PG, Chiquet-Ehrismann R, Tucker RP, Adams JC (2010) The evolution of extracellular matrix. Mol Biol Cell 21(24):4300–4305
Whittaker CA, Bergeron KF, Whittle J, Brandhorst BP, Burke RD, Hynes RO (2006) The echinoderm adhesome. Dev Biol 300(1):252–266
Rozario T, DeSimone DW (2010) The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol 341(1):126–140
Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating MT (1998) Elastin is an essential determinant of arterial morphogenesis. Nature 393(6682):276–280
Debelle L, Tamburro AM (1999) Elastin: molecular description and function. Int J Biochem Cell Biol 31(2):261–272
Pankov R, Yamada KM (2002) Fibronectin at a glance. J Cell Sci 115(Pt 20):3861–3863
Tsang KY, Cheung MC, Chan D, Cheah KS (2010) The developmental roles of the extracellular matrix: beyond structure to regulation. Cell Tissue Res 339(1):93–110
Levick JR (1987) Flow through interstitium and other fibrous matrices. Q J Exp Physiol 72(4):409–437
Iozzo RV, Murdoch AD (1996) Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J 10(5):598–614
Hayen W, Goebeler M, Kumar S, Riessen R, Nehls V (1999) Hyaluronan stimulates tumor cell migration by modulating the fibrin fiber architecture. J Cell Sci 112(Pt 13):2241–2251
Toole BP (2001) Hyaluronan in morphogenesis. Semin Cell Dev Biol 12(2):79–87
Vuorio E, de Crombrugghe B (1990) The family of collagen genes. Annu Rev Biochem 59:837–872
Barocas VH, Tranquillo RT (1997) An anisotropic biphasic theory of tissue-equivalent mechanics: the interplay among cell traction, fibrillar network deformation, fibril alignment, and cell contact guidance. J Biomech Eng 119(2):137–145
Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200(4):423–428
Xu R, Boudreau A, Bissell MJ (2009) Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 28(1–2):167–176
Hagios C, Lochter A, Bissell MJ (1998) Tissue architecture: the ultimate regulator of epithelial function? Philos Trans R Soc Lond B Biol Sci 353(1370):857–870
Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343–356
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284(5751):67–68
Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18(6):884–901
Lopez JI, Kang I, You WK, McDonald DM, Weaver VM (2011) In situ force mapping of mammary gland transformation. Integr Biol (Camb) 3(9):910–921
Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573
Coussens LM, Werb Z (1996) Matrix metalloproteinases and the development of cancer. Chem Biol 3(11):895–904
Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31):5287–5297
Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S, Libra M (2008) Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14(22):7470–7480
Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518–524
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115(1):44–55
Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate mmp-3-induced emt and genomic instability. Nature 436(7047):123–127
Weigelt B, Peterse JL, van’t Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5(8):591–602
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277(5323):225–228
Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V (2000) Role of cell surface metalloprotease mt1-mmp in epithelial cell migration over laminin-5. J Cell Biol 148(3):615–624
Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M (2001) Membrane-type 1 matrix metalloproteinase cleaves cd44 and promotes cell migration. J Cell Biol 153(5):893–904
Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT (1997) Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 94(15):7959–7964
Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase mmp-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85(5):683–693
Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for cd44-mediated tumor invasion. Genes Dev 13(1):35–48
Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A (2005) Par1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313
Dufour A, Sampson NS, Zucker S, Cao J (2008) Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol 217(3):643–651
Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265–273
Birchmeier C, Birchmeier W, Brand-Saberi B (1996) Epithelial-mesenchymal transitions in cancer progression. Acta Anat (Basel) 156(3):217–226
Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139(7):1861–1872
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M (2001) Release of an invasion promoter e-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114(Pt 1):111–118
Bergers G, Coussens LM (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev 10(1):120–127
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR (2007) Association of extracellular cleavage of e-cadherin mediated by mmp-7 with hgf-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 39(4):208–215
Zavadil J, Bottinger EP (2005) Tgf-beta and epithelial-to-mesenchymal transitions. Oncogene 24(37):5764–5774
Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S (2005) Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129(5):1375–1383
Peinado H, Quintanilla M, Cano A (2003) Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 278(23):21113–21123
van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W (2009) Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 28(45):4022–4033
Illman SA, Lehti K, Keski-Oja J, Lohi J (2006) Epilysin (mmp-28) induces tgf-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18):3856–3865
Kim J, Yu W, Kovalski K, Ossowski L (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative pcr-based assay. Cell 94(3):353–362
Tsunezuka Y, Kinoh H, Takino T, Watanabe Y, Okada Y, Shinagawa A, Sato H, Seiki M (1996) Expression of membrane-type matrix metalloproteinase 1 (mt1-mmp) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56(24):5678–5683
Tien YW, Lee PH, Hu RH, Hsu SM, Chang KJ (2003) The role of gelatinase in hepatic metastasis of colorectal cancer. Clin Cancer Res 9(13):4891–4896
Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I (2004) Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of mmp-9: evidence for a role of hepatocyte growth factor. Leukemia 18(5):976–982
Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH (2001) A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61(1):237–242
Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates tgf-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176
Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in t cells. Nat Med 7(10):1118–1122
Kataoka H, Uchino H, Iwamura T, Seiki M, Nabeshima K, Koono M (1999) Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity. Am J Pathol 154(2):457–468
Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48(5–6):411–424
Suzuki M, Raab G, Moses MA, Fernandez CA, Klagsbrun M (1997) Matrix metalloproteinase-3 releases active heparin-binding egf-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem 272(50):31730–31737
Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I (2002) Cd44 anchors the assembly of matrilysin/mmp-7 with heparin-binding epidermal growth factor precursor and erbb4 and regulates female reproductive organ remodeling. Genes Dev 16(3):307–323
Thrailkill KM, Quarles LD, Nagase H, Suzuki K, Serra DM, Fowlkes JL (1995) Characterization of insulin-like growth factor-binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology 136(8):3527–3533
Fowlkes JL, Enghild JJ, Suzuki K, Nagase H (1994) Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 269(41):25742–25746
Manes S, Mira E, Barbacid MM, Cipres A, Fernandez-Resa P, Buesa JM, Merida I, Aracil M, Marquez G, Martinez AC (1997) Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 272(41):25706–25712
Manes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in du-145 carcinoma cells. J Biol Chem 274(11):6935–6945
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174
Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380
Bikfalvi A (2012) Angiogenesis and invasion in cancer. Handb Clin Neurol 104:35–43
Genis L, Gonzalo P, Tutor AS, Galvez BG, Martinez-Ruiz A, Zaragoza C, Lamas S, Tryggvason K, Apte SS, Arroyo AG (2007) Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. Blood 110(8):2916–2923
van Hinsbergh VW, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203–212
Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267(36):26031–26037
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744
Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271(17):10079–10086
Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, Giaccia AJ, Koong AC (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69(1):167–175
Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B, Cao H, Trotti A, Erler JT, Chung CH, Dicker A, Pajak TF, Giaccia AJ, Ang KK (2009) Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: radiation therapy oncology group trial 90-03. J Clin Oncol 27(26):4281–4286
Zhu GG, Risteli L, Makinen M, Risteli J, Kauppila A, Stenback F (1995) Immunohistochemical study of type i collagen and type i pn-collagen in benign and malignant ovarian neoplasms. Cancer 75(4):1010–1017
Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L (1998) Aberrant type i and type iii collagen gene expression in human breast cancer in vivo. J Pathol 186(3):262–268
Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM (2010) A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One 5(3):e9808
Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ (2002) A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62(15):4478–4483
Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, Kirschmann DA (2005) Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65(24):11429–11436
Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22
Laufs S, Schumacher J, Allgayer H (2006) Urokinase-receptor (u-par): an essential player in multiple games of cancer: A review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5(16):1760–1771
Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72(1):1–22
Schmitt M, Janicke F, Graeff H (1990) Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators upa and tpa in human breast cancer. Blood Coagul Fibrinolysis 1(6):695–702
Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S (1999) Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 14(3):535–541
Morita S, Sato A, Hayakawa H, Ihara H, Urano T, Takada Y, Takada A (1998) Cancer cells overexpress mrna of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by northern blotting and in situ hybridization. Int J Cancer 78(3):286–292
Hudson MA, McReynolds LM (1997) Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 89(10):709–717
Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138(5):1059–1067
De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S (1998) Expression of urokinase-type plasminogen activator (u-pa), u-pa receptor, and tissue-type pa messenger rnas in human hepatocellular carcinoma. Cancer Res 58(10):2234–2239
Lakka SS, Bhattacharya A, Mohanam S, Boyd D, Rao JS (2001) Regulation of the upa gene in various grades of human glioma cells. Int J Oncol 18(1):71–79
Zhang X, Bu XY, Zhen HN, Fei Z, Zhang JN, Fu LA (2000) Expression and localisation of urokinase-type plasminogen activator gene in gliomas. J Clin Neurosci 7(2):116–119
Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR (1985) Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 5(6):344–355
Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57(1):25–40
Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM (1992) Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11(13):4825–4833
Gold LI, Schwimmer R, Quigley JP (1989) Human plasma fibronectin as a substrate for human urokinase. Biochem J 262(2):529–534
Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10(3):145–155
Gunzler WA, Steffens GJ, Otting F, Kim SM, Frankus E, Flohe L (1982) The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the a chain. Hoppe Seylers Z Physiol Chem 363(10):1155–1165
He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI (1989) Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A 86(8):2632–2636
Matrisian LM, Bowden GT (1990) Stromelysin/transin and tumor progression. Semin Cancer Biol 1(2):107–115
Baramova EN, Bajou K, Remacle A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM (1997) Involvement of pa/plasmin system in the processing of pro-mmp-9 and in the second step of pro-mmp-2 activation. FEBS Lett 405(2):157–162
Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M (1998) In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 75(3):418–431
Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17(4):439–444
Turk V, Turk B, Turk D (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20(17):4629–4633
Turk D, Guncar G (2003) Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr D Biol Crystallogr 59(Pt 2):203–213
Turk V, Turk B, Guncar G, Turk D, Kos J (2002) Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 42:285–303
Honey K, Rudensky AY (2003) Lysosomal cysteine proteases regulate antigen presentation. Nat Rev Immunol 3(6):472–482
Stoch SA, Wagner JA (2008) Cathepsin k inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83(1):172–176
Deal C (2009) Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol 5(1):20–27
Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, Peters C, Saftig P, Brix K (2003) Thyroid functions of mouse cathepsins b, k, and l. J Clin Invest 111(11):1733–1745
Funkelstein L, Toneff T, Mosier C, Hwang SR, Beuschlein F, Lichtenauer UD, Reinheckel T, Peters C, Hook V (2008) Major role of cathepsin l for producing the peptide hormones acth, beta-endorphin, and alpha-msh, illustrated by protease gene knockout and expression. J Biol Chem 283(51):35652–35659
Mohamed MM, Sloane BF (2006) Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 6(10):764–775
Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6(1):60–64
Jedeszko C, Sloane BF (2004) Cysteine cathepsins in human cancer. Biol Chem 385(11):1017–1027
Mort JS, Recklies AD, Poole AR (1985) Release of cathepsin b precursors from human and murine tumours. Prog Clin Biol Res 180:243–245
Mai J, Finley RL Jr, Waisman DM, Sloane BF (2000) Human procathepsin b interacts with the annexin ii tetramer on the surface of tumor cells. J Biol Chem 275(17):12806–12812
Lah TT, Buck MR, Honn KV, Crissman JD, Rao NC, Liotta LA, Sloane BF (1989) Degradation of laminin by human tumor cathepsin b. Clin Exp Metastasis 7(4):461–468
Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF (1992) Degradation of extracellular-matrix proteins by human cathepsin b from normal and tumour tissues. Biochem J 282(Pt 1):273–278
Ishidoh K, Kominami E (1995) Procathepsin l degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem Biophys Res Commun 217(2):624–631
Mai J, Sameni M, Mikkelsen T, Sloane BF (2002) Degradation of extracellular matrix protein tenascin-c by cathepsin b: an interaction involved in the progression of gliomas. Biol Chem 383(9):1407–1413
Guinec N, Dalet-Fumeron V, Pagano M (1993) “In vitro” study of basement membrane degradation by the cysteine proteinases, cathepsins b, b-like and l. Digestion of collagen iv, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler 374(12):1135–1146
Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA (2006) Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 20(5):543–556
Eeckhout Y, Vaes G (1977) Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin b, plasmin and kallikrein, and spontaneous activation. Biochem J 166(1):21–31
Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T (1993) Effects of membrane-associated cathepsin b on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1178(1):55–62
Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ Jr (2002) Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betal a process initiated by the exocytosis of cathepsin b. J Biol Chem 277(17):14829–14837
Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3(7):489–501
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Choi, IK., Yun, CO. (2013). Role of the Extracellular Matrix: Enzyme Activities and Metastasis. In: Bae, Y., Mrsny, R., Park, K. (eds) Cancer Targeted Drug Delivery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7876-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7876-8_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7875-1
Online ISBN: 978-1-4614-7876-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)